Whitebox Advisors LLC Has $9.60 Million Stock Holdings in Bausch Health Companies Inc. (NYSE:BHC)

Whitebox Advisors LLC trimmed its stake in shares of Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 17.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,190,809 shares of the company's stock after selling 245,978 shares during the period. Whitebox Advisors LLC owned approximately 0.33% of Bausch Health Companies worth $9,598,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Geode Capital Management LLC lifted its position in Bausch Health Companies by 20.5% during the 3rd quarter. Geode Capital Management LLC now owns 636,082 shares of the company's stock valued at $6,448,000 after purchasing an additional 108,269 shares during the period. Range Financial Group LLC bought a new position in Bausch Health Companies in the fourth quarter valued at approximately $1,004,000. Sanders Morris Harris LLC grew its holdings in Bausch Health Companies by 16.0% during the 4th quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company's stock worth $234,000 after acquiring an additional 4,000 shares during the period. Merit Financial Group LLC bought a new stake in shares of Bausch Health Companies during the 4th quarter valued at $228,000. Finally, SG Americas Securities LLC lifted its stake in shares of Bausch Health Companies by 62.0% in the 4th quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company's stock valued at $26,614,000 after purchasing an additional 1,263,706 shares during the period. 78.65% of the stock is owned by institutional investors.

Analyst Ratings Changes

BHC has been the subject of a number of analyst reports. StockNews.com raised Bausch Health Companies from a "hold" rating to a "buy" rating in a research note on Thursday, May 1st. Jefferies Financial Group reaffirmed a "hold" rating and issued a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. Finally, Royal Bank of Canada boosted their price objective on shares of Bausch Health Companies from $8.50 to $10.00 and gave the company a "sector perform" rating in a report on Friday. One analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, Bausch Health Companies presently has a consensus rating of "Hold" and an average price target of $7.42.

Bausch Health Companies Stock Down 4.6 %

Shares of NYSE:BHC traded down $0.23 during midday trading on Tuesday, reaching $4.71. 822,585 shares of the company were exchanged, compared to its average volume of 2,675,041. The firm has a market cap of $1.74 billion, a PE ratio of -39.29, a P/E/G ratio of 0.37 and a beta of 0.34. The stock has a fifty day simple moving average of $6.00 and a two-hundred day simple moving average of $7.18. Bausch Health Companies Inc. has a fifty-two week low of $3.96 and a fifty-two week high of $9.85.

Bausch Health Companies (NYSE:BHC - Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. The company had revenue of $2.56 billion during the quarter, compared to the consensus estimate of $2.51 billion. As a group, analysts forecast that Bausch Health Companies Inc. will post 4.41 earnings per share for the current year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.